1. In Vivo
  2. >>Innovation

R&D Meets The Crowdscape: BioMed X Looks Outside For Insight

An extended inter-disciplinary approach to preclinical research may offer the best leads against today’s biggest challenges in medicine.

 
• By William Looney

It is a cliché to say that pharma science loves to collaborate – the hard thing is that leaky decision framework by which good ideas do not get executed.

Crowdsource
Crowd science appeals as a remedy for declining productivity in the biopharma pipeline • Source: Gayle Rembold Furbert

Solving hard problems in biopharma usually starts like this: expert teams of specialists develop a research premise, test it in a carefully-defined cohort of patients and then validate the results using standard randomized methodologies. Failure rates are high because, at heart, drug research remains a messy exercise in improvisation. That is because we still do not know the basics of how nature uses physics to make the biology that determines individual health status.

Given the sheer number of variables in disease causation, an extended inter-disciplinary approach to preclinical research may offer the best...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By David Wild

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.